GT Biopharma sells $7.45 million of convertible preferred stock and warrants privately
GT Biopharma entered into a securities purchase agreement on September 14, 2026, selling Series M 10% convertible preferred stock and warrants for an aggregate purchase price of $7,450,000, with up to $30,000,000 more available to purchasers through greenshoe rights. The preferred stock converts at an initial price of $6.10 per share and carries full ratchet price protection, so the potential dilution to existing shareholders could be substantial; the company also agreed to seek shareholder approval for issuances above 19.99% of outstanding common stock.
Key points
- Aggregate purchase price of $7,450,000 for preferred stock and warrants with stated value of $8,277,778
- Preferred stock and warrants have an initial price of $6.10 per share and full ratchet price protection
- Purchasers may buy up to $33,333,333 of additional preferred stock for $30,000,000 under greenshoe rights
- Company agreed to hold a stockholder meeting seeking approval for issuances above 19.99% of outstanding common stock
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.